Publications

Featured Publications

Tripartite figure from the publication listed in the caption showing data collection, autoencoder pre-training, autoencoder alignment training, latent space clustering analysis, and cross-modal translation.

Figure 1 from Johnson WC, Alivisatos A, Smith TC 2nd, Van N, Soni V, Wallach JB, Clark NA, Fitzgerald TA, Whiteley JJ, Sokolov A, Ando DM, Schnappinger D, Rhee KY, Aldridge BB. Integration of multi-modal measurements identifies critical mechanisms of tuberculosis drug action. Cell Syst. 2025;16(8):101348. doi: 10.1016/j.cels.2025.101348

Figure 1 from the paper mentioned in the caption, titled "Measurement of growth characteristics of Mtb (video set A)."

Figure 1 from Chung ES, Kar P, Kamkaew M, Amir A, Aldridge BB. Single-cell imaging of the Mycobacterium tuberculosis cell cycle reveals linear and heterogenous growth. Nat Microbiol. 2024;9(12). doi: 10.1038/s41564-024-01846-z.

Graphical abstract of the paper listed below, showing the path of data into a machine learning structure to yield high-order design rules and high-order predictions.

Graphical abstract from Larkins-Ford J, Degefu YN, Van N, Sokolov A, Aldridge BB. Design principles to assemble drug combinations for effective tuberculosis therapy using interpretable pairwise drug response measurements. Cell Rep Med. 2022;3(9). doi: 10.1016/j.xcrm.2022.100737.

Pre-Print

Yoon MH, Culviner PH, Moraes MP, Nitta H, Fortune SM, Thuong NTT, Aldridge BB. Strain diversity drives heterogeneous responses to tuberculosis combination therapy. bioRxiv. 2025. doi: 10.1101/2025.10.06.680645.

Chung ES, Johnson WC, Kamkaew M, McNellis ME, Smith TC 2nd, Vijay S, Thuong NTT, Tan S, Aldridge BB. Increased proportion of growth-arrested bacilli in acidic pH adaptation promotes Mycobacterium tuberculosis treatment survival. bioRxiv. 2025. doi: 10.1101/2025.07.14.664820.

Wei Z, Ektefaie Y, Zhou A, Negatu D, Aldridge B, Dick T, Skarlinski M, White AD, Rodriques S, Hosseiniporgham S, Krieger I, Sacchettini J, Zitnik M, Farhat M. Fleming: An AI Agent for Antibiotic Discovery in Mycobacterium tuberculosis. bioRxiv. 2025. doi: 10.1101/2025.04.01.646719.

Jain N, Ogbonna EC, Maliga Z, Jacobson C, Zhang L, Shih A, Rosenberg J, Kalam H, Gagné A, Solomon IH, Santagata S, Sorger PK, Aldridge BB, Martinot AJ. Multiomic analysis identifies suppressive myeloid cell populations in human TB granulomas. bioRxiv. 2025. doi: 10.1101/2025.03.10.642376.

Publications

Johnson WC, Alivisatos A, Smith TC 2nd, Van N, Soni V, Wallach JB, Clark NA, Fitzgerald TA, Whiteley JJ, Sokolov A, Ando DM, Schnappinger D, Rhee KY, Aldridge BB. Integration of multi-modal measurements identifies critical mechanisms of tuberculosis drug action. Cell Syst. 2025;16(8):101348. doi: 10.1016/j.cels.2025.101348. PMID: 40738114, PMCID PMC12365861, NIHMSID: 2100790.

Lamprecht DA, Wall RJ, Leemans A, Truebody B, Sprangers J, Fiogbe P, Davies C, Wetzel J, Daems S, Pearson W, Pillay V, Saylock S, Ricketts MD, Davis E, Huff A, Grell T, Lin S, Gerber M, Vos A, Dallow J, Willcocks SJ, Roubert C, Sans S, Desorme A, Chappat N, Ray A, Moraes MP, Washington T, D’Erasmo H, Sancheti P, Everaerts M, Monshouwer M, Esquivias J, Larrouy-Maumus G, Draghia Akli R, Fletcher H, Pym AS, Aldridge BB, Sarathy JP, Clancy KW, Stoops B, Dhar N, Steyn AJC, Jackson P, Aguilar-Pérez C, Koul A. Targeting de novo purine biosynthesis for tuberculosis treatment. Nature. 2025;644(8075):214-220. doi: 10.1038/s41586-025-09177-7. PMID: 40533558, PMCID PMC12328218.

Peroutka-Bigus N, Brooks EJ, Ramey ME, D’Erasmo H, Ernest JP, Bauman AA, Woolhiser LK, Savic RM, Lenaerts AJ, Aldridge BB, Sarathy JP, Robertson GT. Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease. Antimicrob Agents Chemother. 2025;69(5):e0190124. doi: 10.1128/aac.01901-24. PMID: 40135920, PMCID: PMC12057366.

Ribis JW, Nieto-Acuña CA, Dong Q, DiBenedetto NC, Mehra A, Nagawa I, El Meouche I, Aldridge BB, Dunlop MJ, Tamayo R, Singh A, Shen A. Unique growth and morphology properties of Clade 5 Clostridioides difficile strains revealed by single-cell time-lapse microscopy. PLoS Pathog. 2025;21(5):e1013155. doi: 10.1371/journal.ppat.1013155. PMID: 40397889, PMCID: PMC12140426.

Tse MW, Zhu M, Peters B, Hamami E, Chen J, Davis KP, Nitz S, Weller J, Warrier T, Hunt DK, Morales Y, Kawate T, Gaulin JL, Come JH, Hernandez-Bird J, Huo W, Neisewander I, Yu X, Aceves-Salvador JA, Kiessling LL, Hung DT, Mecsas J, Aldridge BB, Isberg RR, Blainey PC. Large-scale combination screens reveal small-molecule sensitization of antibiotic-resistant gram-negative ESKAPE pathogens. Proc Natl Acad Sci U S A. 2025;122(13):e2402017122. doi: 10.1073/pnas.2402017122. PMID: 40127266, PMCID: PMC12002207.

Goh JJN, Patel A, Ngara B, van Wijk RC, Strydom N, Wang Q, Van N, Washington TM, Nuermberger EL, Aldridge BB, Roubert C, Sarathy J, Dartois V, Savic RM. Predicting tuberculosis drug efficacy in preclinical and clinical models from in vitro data. iScience. 2025;28(3):111932. doi: 10.1016/j.isci.2025.111932. PMID: 40034847, PMCID: PMC11875147.

Chung ES, Kar P, Kamkaew M, Amir A, Aldridge BB. Single-cell imaging of the Mycobacterium tuberculosis cell cycle reveals linear and heterogenous growth. Nat Microbiol. 2024;9(12):3332-3344. doi: 10.1038/s41564-024-01846-z. PMID: 39548343, PMCID: PMC11602732.

Davis KP, McDermott LA, Snydman DR, Aldridge BB. In vitro identification of underutilized β-lactam combinations against methicillin-resistant Staphylococcus aureus bacteremia isolates. Microbiol Spectr. 2024;12(8):e0097624. doi: 10.1128/spectrum.00976-24. PMID: 38916355, PMCID: PMC11302340.

Davis KP, Morales Y, Ende RJ, Peters R, McCabe AL, Mecsas J, Aldridge BB. Critical role of growth medium for detecting drug interactions in Gram-negative bacteria that model in vivo responses. mBio. 2024;15(3):e0015924. doi: 10.1128/mbio.00159-24. PMID: 38364199, PMCID: PMC10936441.

Janakiraman S, Engels S, Nanda P, Budak M, Greenstein T, Moraes MP, Aldridge BB, Kirschner DE. Semi-automated colony-forming unit counting for biosafety level 3 laboratories. STAR protoc. 2023;4(3):102442. doi: 10.1016/j.xpro.2023.102442. PMID: 37549035, PMCID: PMC10424145.

Van N, Degefu YN, Leus PA, Larkins-Ford J, Klickstein J, Maurer FP, Stone D, Poonawala H, Thorpe CM, Smith TC 2nd, Aldridge BB. Novel synergies and isolate specificities in the drug interactions landscape of Mycobacterium abscessus. Antimicrob Agents Chemother. 2023;67(7):e0009023. doi: 10.1128/aac.00090-23. PMID: 37278639, PMCID: PMC10353461.

Darwin KH, Aldridge B, Seeliger J, Shen A, Stanley S. Confusion. (Can we do better when it comes to the “other-race effect”?) EMBO Rep. 2023;24(4):e57041. doi: 10.15252/embr.202357041. PMID: 36876580, PMCID: PMC10074050.

Kuchina A, Yang J, Aldridge BB, Janes KA, Subramanian N, Krogan NJ, Bouhaddou M, Einav S, Papin J, Germain RN. How can systems approaches help us understand and treat infectious disease? Cell Syst. 2022;13(12):945-949. doi: 10.1016/j.cels.2022.11.009. PMID: 36549272.

Larkins-Ford J, Aldridge BB. Advances in the design of combination therapies for the treatment of tuberculosis. Expert Opin Drug Discov. 2023;18(1):83-97. doi: 10.1080/17460441.2023.2157811. PMID: 36538813, PMCID:  PMC9892364.

Greenstein T, Aldridge BB. Tools to develop antibiotic combinations that target drug tolerance in Mycobacterium tuberculosis. Front Cell Infect Microbiol. 2023;12:1085946. doi: 10.3389/fcimb.2022.1085946. PMID: 36733851, PMCID: PMC9888313.

Liu Q, Zhu J, Dulberger CL, Stanley S, Wilson S, Chung ES, Wang X, Culviner P, Liu YJ, Hicks ND, Babunovic GH, Giffen SR, Aldridge BB, Garner EC, Rubin EJ, Chao MC, Fortune SM. Tuberculosis treatment failure associated with evolution of antibiotic resilience. Science. 2022;378(6624):1111-1118. doi: 10.1126/science.abq2787. PMID:  36480634, PMCID:  PMC9968493.

Larkins-Ford J, Degefu YN, Van N, Sokolov A, Aldridge BB. Design principles to assemble drug combinations for effective tuberculosis therapy using interpretable pairwise drug response measurements. Cell Rep Med. 2022;3(9):100737. doi: 10.1016/j.xcrm.2022.100737. PMID: 36084643, PMCID:  PMC9512659.

Paulowski L, Beckham KSH, Johansen MD, Berneking L, Van N, Degefu Y, Staack S, Sotomayor FV, Asar L, Rohde H, Aldridge BB, Aepfelbacher M, Parret A, Wilmanns M, Kremer L, Combrink K, Maurer FP. C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus. PNAS Nexus. 2022;1(4):pgac130. doi: 10.1093/pnasnexus/pgac130. PMID:  36714853, PMCID:  PMC9802118.

Kriel NL, Newton-Foot M, Bennion OT, Aldridge BB, Mehaffy C, Belisle JT, Walzl G, Warren RM, Sampson SL, Gey van Pittius NC. Localization of EccA₃ at the growing pole in Mycobacterium smegmatis. BMC Microbiol. 2022;22(1):140. doi: 10.1186/s12866-022-02554-6. PMID: 35590245, PMCID:  PMC9118679.

Chung ES, Johnson WC, Aldridge BB. Types and functions of heterogeneity in mycobacteria. Nat Rev Microbiol. 2022;20(9):529-541. doi: 10.1038/s41579-022-00721-0. PMID:  35365812, PMCID: PMC9681535.

Davis K, Greenstein T, Colindres RV, Aldridge BB. Leveraging laboratory and clinical studies to design effective antibiotic combination therapy. Curr Opin Microbiol. 2021;(64):68-75. doi: 10.1016/j.mib.2021.09.006. PMID: 34628295, PMCID:  PMC8671129.

Li M, Patel HV, Cognetta AB 3rd, Smith TC 2nd, Mallick I, Cavalier JF, Previti ML, Canaan S, Aldridge BB, Cravatt BF, Seeliger JC. Identification of cell wall synthesis inhibitors active against Mycobacterium tuberculosis by competitive activity-based protein profiling. Cell Chem Biol. 2022;29(5):883-896.e5. doi: 10.1016/j.chembiol.2021.09.002. PMID: 34599873, PMICD: PMC8964833.

Larkins-Ford J, Greenstein T, Van N, Degefu YN, Olson MC, Sokolov A, Aldridge BB. Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis. Cell Syst. 2021;29(5):1046-1063.e7. doi: 10.1016/j.cels.2021.08.004. PMID: 34469743, PMCID: PMC8617591.

Preview Consequential drug combinations for tuberculosis treatments

Egbelowo O, Sarathy JP, Gausi K, Zimmerman MD, Wang H, Wijnant GJ, Kaya F, Gengenbacher M, Van N, Degefu Y, Nacy C, Aldridge BB, Carter CL, Denti P, Dartois V. Pharmacokinetics and target attainment of SQ109 in plasma and human-like tuberculosis lesions in rabbits. Antimicrob Agents Chemother. 2021;65(9):e0002421. doi: 10.1128/AAC.00024-21. PMID: 34228540, PMCID: PMC8370215. 

Van N, Degefu YN, Aldridge BB. Efficient Measurement of Drug Interactions with DiaMOND (Diagonal Measurement of N-Way Drug Interactions). In: Parish T, Kumar A (eds). Mycobacteria Protocols. Methods in Molecular Biology, vol 2314. Humana, New York, NY. 2021.

Aldridge BB, Barros-Aguirre D, Barry CE 3rd, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu XJ, Cooper CB, Dartois V, Duncan K, Fotouhi N, Gusovsky F, Hipskind PA, Kempf DJ, Lelièvre J, Lenaerts AJ, McNamara CW, Mizrahi V, Nathan C, Olsen DB, Parish T, Petrassi HM, Pym A, Rhee KY, Robertson GT, Rock JM, Rubin EJ, Russell B, Russell DG, Sacchettini JC, Schnappinger D, Schrimpf M, Upton AM, Warner P, Wyatt PG, Yuan Y. The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 2021;27(8):1333-1337. doi: 10.1038/s41591-021-01442-2. PMID: 34226736, PMCID: PMC10478072.

Smith TC 2nd, Pullen KM, Olson MC, McNellis ME, Richardson I, Hu S, Larkins-Ford J, Wang X, Freundlich JS, Ando DM, Aldridge BB. Morphological profiling of tubercle bacilli identifies drug pathways of action. Proc Natl Acad Sci U S A. 2020;117(31):18744-18753. doi: 10.1073/pnas.2002738117. PMID: 32680963, PMCID: PMC7414088.

Goliaei A, Woods HA, Tron AE, Belmonte MA, Secrist JP, Ferguson D, Drew L, Fretland AJ, Aldridge BB, Gibbons FD. Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl‐1 Inhibitor AZD5991. CPT Pharmacometrics Syst Pharmacol. 2020;9(10):561-570. doi: 10.1002/psp4.12552. PMID: 32860732, PMCID:  PMC7577016. 

Ma S, Jaipall S, Larkins-Ford J, Lohmiller J, Aldridge BB, Sherman D, Chandrasekaran. Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis. mBio. 2019;10(6):e02627-19. doi: 10.1128/mBio.02627-19. PMID: 31719182, PMC6851285.

De Rycker M, Horn D, Aldridge B, Amewu RK, Barry C 3rd, Buckner F, Cook S, Ferguson M, Gobeau N, Herrmann J, Herrling P, Hope W, Keiser J, Lafuente-Monasterio MJ, Leeson P, Leroy D, Manjunatha U, McCarthy J, Miles T, Mizrahi V, Moshynets O, Niles J, Overington J, Pottage J, Rao S, Read K, Ribeiro I, Silver L, Southern J, Spangenberg T, Sundar S, Taylor C, Van Voorhis W, White N, Wyllie S, Wyatt P, Gilbert I. Setting Our Sights on Infectious Diseases. ACS Infect Dis. 2020;6(1):3-13. doi: 10.1021/acsinfecdis.9b00371. PMID: 31808676, PMCID: PMC6958537.

Smith TC 2nd, Aldridge BB. Targeting drugs for tuberculosis. Science. 2019;364(6447):1234-1235. doi: 10.1126/science.aay0211. PMID: 31249047. free full text

Balaban NQ, Helaine S, Lewis K, Ackermann M, Aldridge B, Andersson DI, Brynildsen MP, Bumann D, Camilli A, Collins JJ, Dehio C, Fortune S, Ghigo JM, Hardt WD, Harms A, Heinemann M, Hung DT, Jenal U, Levin BR, Michiels J, Storz G, Tan MW, Tenson T, Van Melderen L, Zinkernagel A. Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol. 2019;17(7):441-448. doi: 10.1038/s41579-019-0196-3. PMID: 30980069, PMCID: PMC7136161.

Katzir I, Cokol M, Aldridge BB, Alon U. Prediction of ultra-high-order antibiotic combinations based on pairwise interactions. PLoS Comput Biol. 2019;15(1):e1006774. doi: 10.1371/journal.pcbi.1006774. PMID: 30699106, PMCID: PMC6370231.

Boot M, Commandeur S, Subudhi AK, Bahira M, Smith TC 2nd, Abdallah AM, van Gemert M, Lelièvre J, Ballell L, Aldridge BB, Pain A, Speer A, Bitter W. Accelerating early anti-tuberculosis drug discovery by creating mycobacterial indicator strains that predict mode of action. Antimicrob Agents Chemother. 2018;62(7):e00083-18. doi: 10.1128/AAC.00083-18. PMID: 29661879, PMCID: PMC6021670.

Logsdon MM, Aldridge BB. Stable Regulation of Cell Cycle Events in Mycobacteria: Insights from Inherently Heterogeneous Bacterial Populations. Front Microbiol. 2018;9:514. doi: 10.3389/fmicb.2018.00514. PMID: 29619019, PMCID: PMC5871693. 

Hayashi JM, Richardson K, Melzer ES, Sandler SJ, Aldridge BB, Siegrist MS, Morita YS. Stress-Induced Reorganization of the Mycobacterial Membrane Domain. mBio. 2018;9(1):e01823-17. doi: 10.1128/mBio.01823-17. PMID: 29362232, PMCID: PMC5784251. 

Sundarakrishnan A, Chen Y, Black LD, Aldridge BB, Kaplan DL. Engineered cell and tissue models of pulmonary fibrosis. Adv Drug Deliv Rev. 2018;129:78-94. doi: 10.1016/j.addr.2017.12.013. PMID: 29269274.

Mann KM, Huang DL, Hooppaw AJ, Logsdon MM, Richardson K, Lee HJ, Kimmey JM, Aldridge BB, Stallings CL. Rv0004 is a new essential member of the mycobacterial DNA replication machinery. PLoS Genet. 2017;13(11):e1007115. doi: 10.1371/journal.pgen.1007115. PMID: 29176877, PMCID: PMC5720831. 

Vijay S, Vinh DN, Hai HT, Ha VTN, Dung VTM, Dinh TD, Nhung HN, Tram TTB, Aldridge BB, Hanh NT, Thu DDA, Phu NH, Thwaites GE, Thuong NTT. Influence of Stress and Antibiotic Resistance on Cell-Length Distribution in Mycobacterium tuberculosis Clinical Isolates. Front Microbiol. 2017;8:2296. doi: 10.3389/fmicb.2017.02296. PMID: 29209302, PMCID: PMC5702322. 

Logsdon MM, Ho PY, Papavinasasundaram K, Richardson K, Cokol M, Sassetti CM, Amir A, Aldridge BB. A parallel adder coordinates mycobacterial cell cycle progression and cell size homeostasis in the context of asymmetric growth and organization. Curr Biol. 2017;27(21):3367-3374.e7. doi: 10.1016/j.cub.2017.09.046. PMID: 29107550, PMCID: PMC5687851, NIHMSID: NIHMS909457.

Cokol M, Kuru N, Bicak E, Larkins-Ford J, Aldridge BB. Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis. Sci Adv. 2017;3(10):e1701881. doi: 10.1126/sciadv.1701881. PMID: 29026882, PMCID: PMC5636204. 

Richardson K, Bennion OT, Tan S, Hoang AN, Cokol M, Aldridge BB. Temporal and intrinsic factors of rifampicin tolerance in mycobacteria. Proc Natl Acad Sci U S A. 2016;113(29):8302-7. doi: 10.1073/pnas.1600372113. PMID: 27357669, PMCID: PMC4961206.

Hayashi JM, Luo CY, Mayfield JA, Hsu T, Fukuda T, Walfield AL, Giffen SR, Leszyk JD, Baer CE, Bennion OT, Madduri A, Shaffer SA, Aldridge BB, Sassetti CM, Sandler SJ, Kinoshita T, Moody DB, Morita YS. Spatially distinct and metabolically active membrane domain in mycobacteria. Proc Natl Acad Sci U S A. 2016;113(19):5400-5. doi: 10.1073/pnas.1525165113. PMID: 27114527, PMCID: PMC4868426. 

Aldridge BB, Keren I, Fortune SM. The Spectrum of Drug Susceptibility in Mycobacteria. Microbiol Spectr. 2014;2(5).doi: 10.1128/microbiolspec.MGM2-0031-2013. PMID: 26104360.

Aldridge BB, Rhee KY. Microbial metabolomics: innovation, application, insight. Curr Opin Microbiol. 2014;19:90-96. doi: 10.1016/j.mib.2014.06.009. PMID: 25016173.

Sukumar N, Tan S, Aldridge BB, Russell DG. Exploitation of Mycobacterium tuberculosis reporter strains to probe the impact of vaccination at sites of infection. PLoS Pathog. 2014;10(9):e1004394. doi: https://doi.org/10.1371/journal.ppat.1004394. PMID: 25233380, PMCID: PMCID PMC4169503.

Chao MC, Kieser KJ, Minami S, Mavrici D, Aldridge BB, Fortune SM, Alber T, Rubin EJ. Protein Complexes and Proteolytic Activation of the Cell Wall Hydrolase RipA Regulate Septal Resolution in Mycobacteria. PLoS Pathog. 2013;9(2):e1003197. doi: 10.1371/journal.ppat.1003197. PMID: 23468634, PMCID: PMC3585148.

Wirth SE, Krywy JA, Aldridge BB, Fortune SM, Fernandez-Suarez M, Gray TA, Derbyshire KM. Polar assembly and scaffolding proteins of the virulence-associated ESX-1 secretory apparatus in mycobacteria. Mol Microbiol. 2012;83(3):654-64. doi: 10.1111/j.1365-2958.2011.07958.x. PMID: 22233444, PMCID: PMC3277861, NIHMSID: NIHMS346555.

Aldridge BB, Fernandez-Suarez M, Heller D, Ambravaneswaran V, Irimia D, Toner M, Fortune SM. Asymmetry and aging in mycobacterial cells lead to variable growth and antibiotic susceptibility. Science. 2012;335(6064):100-4. doi: 10.1126/science.1216166. PMID: 22174129, PMCID: PMC3397429, NIHMSID: NIHMS389397.

Aldridge BB, Gaudet S, Lauffenburger DA, Sorger PK. Lyapunov exponents and phase diagrams reveal multi-factorial control over TRAIL-induced apoptosis. Mol Syst Biol. 2011;7:553. doi: 10.1038/msb.2011.85. PMID: 22108795, PMCID: PMC3261706. 

Aldridge BB, Saez-Rodriguez J, Muhlich JL, Sorger PK, Lauffenburger DA. Fuzzy logic analysis of kinase pathway crosstalk in TNF/EGF/Insulin-induced signaling. PLoS Comput Biol. 2009;5(4):e1000340. doi: 10.1371/journal.pcbi.1000340. PMID: 19343194, PMCID: PMC2663056. 

Albeck JG, Burke JM, Aldridge BB, Zhang M, Lauffenburger DA, Sorger PK. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell. 2008;30(1):11-25. doi: 10.1016/j.molcel.2008.02.012. PMID: 18406323, PMCID: PMC2858979, NIHMSID: NIHMS46984.

Aldridge BB, Burke JM, Lauffenburger DA, Sorger PK. Physicochemical Modelling of Cell Signaling Pathways. Nat Cell Biol. 2006;8(11):1195-203. doi: 10.1038/ncb1497. PMID: 17060902.

Aldridge BB, Haller G, Sorger PK, Lauffenburger DA. Direct Lyapunov exponent analysis enables parametric study of transient signalling governing cell behaviour. Syst Biol (Stevenage). 2006;153(6):425-32. doi: 10.1049/ip-syb:20050065. PMID: 17186704.

Draviam VM, Shapiro I, Aldridge B, Sorger PK. Misorientation and reduced stretching of aligned sister kinetochores promote chromosome missegregation in EB1- or APC-depleted cells. EMBO J. 2006;25(12):2814-27. doi: 10.1038/sj.emboj.7601168. PMID: 16763565, PMCID: PMC1500857. 